ALGN Add to watchlist
$180.59 +0.00 (+0.00%)
Pre-Market: $178.46 2.13 (-1.18%)
Last updated: Jul 15, 2026 10:03
52-Week Range
$178.46
$122.00 $178.46 $208.31

Fundamentals Overview

Align Technology, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 29.7 PEG 5.99 P/B 3.07 P/S 3.12

Intrinsic value (DCF)

-50.4% downside vs price

Profitability

Net margin 10.5%

Risk (Beta)

1.67 — higher vol

Earnings & growth

EPS $6.00 Rev -0.7% Profit -16.9% vs prior qtr

BullzEye Analysis

Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Sell — 74% confidence Risk: High Volatility — Beta 1.67. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: A-

Pressures (Sell):

DCF 50.4% downside vs price · 3M vs S&P 500: -10.8% · 3M vs Healthcare sector: -8.2% · Beta 1.67 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$12.78B
P/E (TTM)
29.73
EPS (TTM)
$6.00
Dividend Yield
N/A
52-Week Range
$122.00 - $208.31
Volume vs Avg
N/A
Beta
1.67

About

Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." ...
Sector: Healthcare
Headquarters: US
Employees: 20,290
IPO Date: Jan 2001
Beta: 1.67 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: mixed. Current institutional positions: Buy: 3, Equal Weight: 6, Hold: 2, Neutral: 2, Outperform: 8, Overweight: 9.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $88.46; current price is $178.46. That’s a -50.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 29.73
DCF value (model) $88.46 (-50.4% vs price)
PEG (TTM) 5.99
P/B (TTM) 3.07
P/S (TTM) 3.12
P/FCF (TTM) 18.63
Liquidity & enterprise
Current Ratio (TTM) 1.39
Quick Ratio (TTM) 1.28
Cash Ratio (TTM) 0.56
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 10.5%
Gross margin (TTM) 67.68%
Operating margin (TTM) 14.44%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ALGN.

Analyst Sentiment at a Glance

A- Sentiment Mixed
Buy 3Equal Weight 6Hold 2Neutral 2Outperform 8Overweight 9
2 upgrades, 2 downgrades
Price Target Consensus
Current $178.46
Median $200.00
Consensus $204.09
Low consensus $185.00
High consensus $235.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-04-30
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-24
Piper Sandler maintain Overweight Overweight 2026-04-21
Barclays upgrade Equal Weight Overweight 2026-03-17
Barclays maintain Equal Weight Equal Weight 2026-02-26
HSBC upgrade Hold Buy 2026-02-09
Piper Sandler maintain Overweight Overweight 2026-02-05
Morgan Stanley maintain Equal Weight Equal Weight 2026-02-05
UBS maintain Neutral Neutral 2026-02-05
Evercore ISI Group maintain Outperform Outperform 2026-02-05
Stifel maintain Buy Buy 2026-02-05
Wells Fargo maintain Overweight Overweight 2026-02-05
Mizuho maintain Outperform Outperform 2026-01-20
Evercore ISI Group maintain Outperform Outperform 2025-10-30
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-30
Piper Sandler maintain Overweight Overweight 2025-10-30
Wells Fargo maintain Overweight Overweight 2025-10-30
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-21
UBS maintain Neutral Neutral 2025-10-16
Mizuho maintain Outperform Outperform 2025-10-13
Jefferies downgrade Buy Hold 2025-10-10
Evercore ISI Group maintain Outperform Outperform 2025-10-08
Stifel maintain Buy Buy 2025-07-31
Morgan Stanley downgrade Overweight Equal Weight 2025-07-31
Piper Sandler maintain Overweight Overweight 2025-07-31
Wells Fargo maintain Overweight Overweight 2025-07-31
Evercore ISI Group maintain Outperform Outperform 2025-07-09
Evercore ISI Group maintain Outperform Outperform 2025-05-01
Piper Sandler maintain Overweight Overweight 2025-05-01
Needham maintain Hold Hold 2025-05-01